GlassScriptPhysician profile
Lixin Zhang
NPI 1154482859
$12,121.72
in general payments reported to CMS, 2019-2025
66 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $1,474 · 2021: $3,544 · 2022: $2,082 · 2023: $1,766 · 2024: $1,040 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,780 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,780.21 |
| Education | $179.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,737.94 | 2021-2025 | Botox, Qulipta, Duopa |
| Teva Pharmaceuticals USA, INC. | $888.50 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $687.77 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $579.81 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $555.43 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $477.55 | 2019-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $435.85 | 2019-2024 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $376.45 | 2019-2025 | Onpattro |
| Lundbeck LLC | $275.34 | 2019-2025 | Vyepti |
| Mdd US Operations, LLC | $269.92 | 2019-2022 | |
| Pfizer INC. | $268.49 | 2019-2025 | |
| Sk Life Science, INC. | $266.28 | 2020-2025 | Xcopri |
| Tanabe Pharma America, INC. | $261.72 | 2019-2024 | |
| Amgen INC. | $253.96 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $238.67 | 2019-2025 | Daybue |
Show all 64 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,620,355.55 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lixin Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.